Vaxcyte's CFO Andrew Guggenhime Buys Shares

Vaxcyte's CFO Andrew Guggenhime purchased 10,000 shares, a move worth $53,500.

Written by EarningsIQ · Published Jun 18, 2026, 9:00 PM EDT · Updated Jun 19, 2026, 12:00 AM EDT

Key Points

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., bought 10,000 shares at $5.35 each on June 18, 2026, totaling $53,500.
Vaxcyte, Inc. trades on NasdaqGS under the ticker PCVX, with a market cap of about $7.32 billion and a 52-week range of $29.08 to $65.00.
Analysts maintain a strong buy consensus for Vaxcyte, with a mean price target of $109 and recent ratings from firms like BTIG and Guggenheim.

On June 18, 2026, Andrew Guggenhime, who serves as the President and CFO of Vaxcyte, Inc. (NasdaqGS: PCVX), made a notable purchase of the company's stock. Guggenhime acquired 10,000 shares at a price of $5.35 per share, with the total transaction valued at $53,500. This insider transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Vaxcyte, Inc.

The recent insider activity at Vaxcyte included several transactions on June 18, 2026. Alongside Andrew Guggenhime's purchase of 10,000 shares for $5.35 each, he also sold 10,000 shares at a different price point. Additionally, Grant Pickering, the CEO, bought 225 shares and sold 23,461 shares under a pre-planned arrangement.

Other Institutional Activity in Vaxcyte

Several institutional funds have also been active in Vaxcyte. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, ending with 16,575,875 shares worth about $960.2 million. FMR LLC added 2,658,347 shares, now holding 16,492,861 shares valued at approximately $958.4 million. T. Rowe Price Investment Management, Inc. grew its position by 829,684 shares, reaching a total of 12,126,017 shares valued at roughly $704.6 million.

Vaxcyte Stock Snapshot

Shares of Vaxcyte, Inc. are trading around $50.67. The company, which operates in the biotechnology sector, has a market capitalization of approximately $7.32 billion. It has a 52-week low of $29.08 and a high of $65.00. The stock's 50-day moving average is $53.89, and its 200-day moving average is $48.95. Vaxcyte has a current ratio of 7.49, indicating strong liquidity.

Analysts Set New Price Targets

Analysts have shown a strong interest in Vaxcyte. On February 26, 2026, BTIG maintained its buy rating with a price target of $89. Guggenheim reiterated a buy rating with a target of $116 on February 2, 2026. Needham also maintained a buy rating, setting a price target of $110 on January 7, 2026. Overall, the consensus among analysts is a strong buy, with a mean price target of $109 based on nine analyst opinions.

About Vaxcyte

Vaxcyte, Inc. is a clinical-stage biotechnology company based in San Carlos, California. It focuses on developing innovative vaccines to prevent and treat bacterial infectious diseases. Its lead candidate, VAX-24, is designed to prevent invasive pneumococcal disease in infants. The company also develops other vaccine candidates targeting various bacterial infections. Vaxcyte is led by CEO Grant E. Pickering and employs around 507 people.

Bottom Line

Andrew Guggenhime's recent purchase of Vaxcyte shares highlights ongoing insider interest in the company. Vaxcyte is a notable player in the biotech space, with a strong market presence and a promising pipeline of vaccine candidates. Investors keep a close eye on insider transactions like these as they often provide insight into company sentiment. Remember, these filings reflect past actions and may not indicate current positions.